Agilent Technologies has announced it has completed the acquisition of BioTek Instruments, a global leader in the design, manufacture and distribution of innovative life science instrumentation.

The BioTek acquisition expands Agilent’s growing presence and expertise in cell analysis and strengthens the company’s position in the large and growing immuno-oncology and immunotherapy areas. The combined portfolio will allow Agilent to deliver a range of unique cell analysis workflows to provide customers the ability to obtain deeper, more reliable insights across a variety of cell analysis applications. This combination expands the company’s presence in biopharma, academia and research, as customers seek to understand complex cellular environments and interactions.

“We’re extremely pleased to add BioTek’s tremendously talented employees and industry leading technologies to the Agilent team,” said Mike McMullen, Agilent president and CEO. “The combination of our two companies and our collective offerings will help lead to a better understanding of cell function, behavior and interactions. This will enable researchers to more quickly achieve significant breakthroughs in solving the most complex health and science challenges.”

In Agilent’s fiscal year fourth quarter, it’s expected that BioTek will contribute approximately $20 million to $25 million to Agilent revenues with no material impact on fourth quarter earnings per share (EPS).